The study compared the safety of denosumab and romosozumab, two biologic drugs used to treat osteoporosis, using the FDA's Adverse Event Reporting System (FAERS) database from the second quarter of 2019 to the second quarter of 2025[8]. The analysis included 38,784 reports for denosumab and 10,007 reports for romosozumab[8]. Denosumab was associated with long-term cumulative risk and showed strong signals in musculoskeletal and metabolic disorders, including osteoimmune complications such as non-infectious gingivitis[8]. In contrast, romosozumab demonstrated an acute and severe cardiovascular risk with strong signals for coronary artery disease and heart failure, while the immune-related risk was limited to minor injection site reactions[8]. Research has revealed distinct differences in the safety profiles of both drugs[8]. The authors of the study recommend that clinical decision makers gain a deeper understanding of these safety characteristics to support personalized therapy and improve drug safety[8].